From: Pulmonary eosinophilia may indicate onset stage of allergic bronchopulmonary aspergillosis
Characteristic | EP group (n = 6) | Non-EP group (n = 19) | |
---|---|---|---|
Recurrence | 4 (67%) | 15 (78%) | ns |
Therapy | |||
Oral corticosteroids | 5 (83%) | 13/19 (68%) | ns |
Anti-fungal drugs | 1 (17%) | 16/19 (84%) | 0.0055 |
Duration (months) before recurrence, median (IQR) | 22.5 (20.5–22.9) | 20.5 (13.8–34.8) | ns |
Total follow-up period (years), median (IQR) | 4.0 (2.6–7.7) | 4.6 (3.1–8.3) | ns |
Recurrence rate/y, median (IQR) | 0.23 (0.10–0.41) | 0.38 (0.14–0.67) | ns |
Phenotype at recurrence | EP: 4/4 (100%) | Non-EP: 16/16 (100%) | 0.0002 |